138 related articles for article (PubMed ID: 3594492)
1. Sensitization of human tumor cells to homologous complement by vaccinia virus treatment.
Okada H; Wakamiya N; Okada N; Kato S
Cancer Immunol Immunother; 1987; 25(1):7-9. PubMed ID: 3594492
[TBL] [Abstract][Full Text] [Related]
2. Tumor cells treated with vaccinia virus can activate the alternative pathway of mouse complement.
Wakamiya N; Okada N; Wang YL; Ito T; Ueda S; Kato S; Okada H
Jpn J Cancer Res; 1989 Aug; 80(8):765-70. PubMed ID: 2511185
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of UV-inactivated vaccinia virus in the modification of tumor cells for augmentation of their immunogenicity.
Wakamiya N; Wang YL; Imai H; Gu HX; Ueda S; Kato S
Cancer Immunol Immunother; 1986; 23(2):125-9. PubMed ID: 3779714
[TBL] [Abstract][Full Text] [Related]
4. Cytolysis of Sendai virus-infected guinea-pig cells by homologous complement.
Okada H; Tanaka H; Okada N
Immunology; 1983 May; 49(1):29-35. PubMed ID: 6301976
[TBL] [Abstract][Full Text] [Related]
5. Protection against vaccinia virus challenge by CD8 memory T cells resolved by molecular mimicry.
Cornberg M; Sheridan BS; Saccoccio FM; Brehm MA; Selin LK
J Virol; 2007 Jan; 81(2):934-44. PubMed ID: 17079318
[TBL] [Abstract][Full Text] [Related]
6. Immune response to vaccinia virus recombinants expressing glycoproteins gE, gB, gH, and gL of Varicella-zoster virus.
Kutinová L; Hainz P; Ludvíková V; Maresová L; Nĕmecková S
Virology; 2001 Feb; 280(2):211-20. PubMed ID: 11162835
[TBL] [Abstract][Full Text] [Related]
7. Homologous and heterologous glycoproteins induce protection against Junin virus challenge in guinea pigs.
López N; Scolaro L; Rossi C; Jácamo R; Candurra N; Pujol C; Damonte EB; Franze-Fernández MT
J Gen Virol; 2000 May; 81(Pt 5):1273-81. PubMed ID: 10769070
[TBL] [Abstract][Full Text] [Related]
8. Antitumor efficacy of two kinds of tumor vaccine modified with vaccinia virus.
Ito T; Okabayashi M; Osada Y; Wakamiya N; Kato S
In Vivo; 1988; 2(5):325-9. PubMed ID: 2979853
[TBL] [Abstract][Full Text] [Related]
9. The role for host-immune factors in the in vivo antiviral effects of tumour necrosis factor.
Lidbury BA; Ramshaw IA; Sambhi SK
Cytokine; 1995 Feb; 7(2):157-64. PubMed ID: 7780035
[TBL] [Abstract][Full Text] [Related]
10. Establishment of tumor-specific immunotherapy model utilizing vaccinia virus-reactive helper T cell activity.
Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
Eur J Immunol; 1988 Nov; 18(11):1773-8. PubMed ID: 2974424
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of C5 complement enhance vaccinia virus oncolysis.
Magge D; Guo ZS; O'Malley ME; Francis L; Ravindranathan R; Bartlett DL
Cancer Gene Ther; 2013 Jun; 20(6):342-50. PubMed ID: 23661042
[TBL] [Abstract][Full Text] [Related]
12. The Vaccinia virus complement control protein modulates adaptive immune responses during infection.
Girgis NM; Dehaven BC; Xiao Y; Alexander E; Viner KM; Isaacs SN
J Virol; 2011 Mar; 85(6):2547-56. PubMed ID: 21191012
[TBL] [Abstract][Full Text] [Related]
13. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
14. The Orf virus E3L homologue is able to complement deletion of the vaccinia virus E3L gene in vitro but not in vivo.
Vijaysri S; Talasela L; Mercer AA; Mcinnes CJ; Jacobs BL; Langland JO
Virology; 2003 Sep; 314(1):305-14. PubMed ID: 14517083
[TBL] [Abstract][Full Text] [Related]
15. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.
Yu F; Wang X; Guo ZS; Bartlett DL; Gottschalk SM; Song XT
Mol Ther; 2014 Jan; 22(1):102-11. PubMed ID: 24135899
[TBL] [Abstract][Full Text] [Related]
16. Vaccinia virus proteins on the plasma membranes of infected cells. II. Expression of viral antigens and killing of infected cells by vaccinia virus-specific cytotoxic T cells.
Mallon VR; Domber EA; Holowczak JA
Virology; 1985 Aug; 145(1):1-23. PubMed ID: 3874471
[TBL] [Abstract][Full Text] [Related]
17. Glycosylated and nonglycosylated complement control protein of the lister strain of vaccinia virus.
Meseda CA; Kuhn J; Atukorale V; Campbell J; Weir JP
Clin Vaccine Immunol; 2014 Sep; 21(9):1330-8. PubMed ID: 25030055
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of cytomegalovirus proteins US2 and US11 point to contributions from direct priming and cross-priming in induction of vaccinia virus-specific CD8(+) T cells.
Basta S; Chen W; Bennink JR; Yewdell JW
J Immunol; 2002 Jun; 168(11):5403-8. PubMed ID: 12023332
[TBL] [Abstract][Full Text] [Related]
19. Vaccinia virus infection of mature dendritic cells results in activation of virus-specific naïve CD8+ T cells: a potential mechanism for direct presentation.
Yates NL; Alexander-Miller MA
Virology; 2007 Mar; 359(2):349-61. PubMed ID: 17056088
[TBL] [Abstract][Full Text] [Related]
20. Innate immunity to viruses: control of vaccinia virus infection by gamma delta T cells.
Selin LK; Santolucito PA; Pinto AK; Szomolanyi-Tsuda E; Welsh RM
J Immunol; 2001 Jun; 166(11):6784-94. PubMed ID: 11359837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
